Home > Journals > European Journal of Physical and Rehabilitation Medicine > Past Issues > European Journal of Physical and Rehabilitation Medicine 2010 September;46(3) > European Journal of Physical and Rehabilitation Medicine 2010 September;46(3):401-10

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE

A Journal on Physical Medicine and Rehabilitation after Pathological Events


Official Journal of the Italian Society of Physical and Rehabilitation Medicine (SIMFER), European Society of Physical and Rehabilitation Medicine (ESPRM), European Union of Medical Specialists - Physical and Rehabilitation Medicine Section (UEMS-PRM), Mediterranean Forum of Physical and Rehabilitation Medicine (MFPRM), Hellenic Society of Physical and Rehabilitation Medicine (EEFIAP)
In association with International Society of Physical and Rehabilitation Medicine (ISPRM)
Indexed/Abstracted in: CINAHL, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,827


eTOC

 

ADVANCES IN THE MANAGEMENT OF SPASTICITY  FREEfree


European Journal of Physical and Rehabilitation Medicine 2010 September;46(3):401-10

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

Managing spasticity with drugs

Simon O., Yelnik A. P.

1 Physical Medicine and Rehabilitation Department, AP-HP, GH Bichat, University Paris7, Paris, France 2 Physical Medicine and Rehabilitation Department, AP-HP, G.H. Lariboisière-F.Widal, University Paris7, Paris, France


FULL TEXT  


Spasticity is a common symptom observed after pyramidal system lesion. The treatment of spasticity has considerably changed during last years, notably with the generalization of Botulinum toxin use. However, the treatment of spasticity should consider all therapeutic possibility in accordance with patient status and objective. Drugs are only a part of the treatment and physical therapy must always be used. Others treatments such as surgery, orthosis, occupational therapy must also be discussed individually. Several guidelines are now available for Botulinum toxin treatment but only the French guidelines consider all drug therapies. This review addresses the different drugs commonly used on the basis of an extensive review of literature. Some facts are clearly established by randomized controlled trials but a certain number of questions remains unclear and only clinical experience and consensus can guide injectors.

top of page

Publication History

Cite this article as

Corresponding author e-mail

olivier.simon@bch.aphp.fr